Since the early nineties, felbamate has been utilized as an effective treatment for refractory partial seizures (with or without generalization). Felbamate's risk of idiosyncratic aplastic anaemia and hepatotoxicity has limited its use. Its highly reactive metabolites are the cause of hepatotoxicity and aplastic anaemia. The study formulated a nose-to-brain felbamate chitosan nanosuspension to increase brain uptake and avoid first-pass metabolism so as to remove risk factors associated with felbamate oral therapy. Felbamate nanosuspension was prepared using chitosan as a mucoadhesive polymer by ionic gelation with magnetic stirring and sonication. Using a micropipette (10-100 µL), the produced nanosuspension was injected into the rats' nostrils, allowing the drug to travel directly from the nose to the brain. The optimized formulations exhibited a bluish transparent appearance, a mean particle size of 115.0 ± 4.37 nm, a PDI of 0.118 ± 0.02, a zeta potential of +34.0 6 ±1.3 mV, and an entrapment efficiency of 90.32%. Felbamate concentration in brain homogenate was calculated using UV/VIS Spectrophotometer. When given as a suspension, felbamate concen6trations in the brain and plasma were 112.56 ± 17.81 and 401.62±20.92 ng/ml, respectively; however, when given as a nanosuspension, these values increased to 400.34±23.67 and 451±21.12 ng/ml, respectively (p < 0.05) after intranasal administration of the same dose. Animals given nanosuspension at several doses showed less amount of drug in other body organ compared to brain and thus targeting of drug to brain and reduce side effects associated with it. These findings suggest that the felbamate-chitosan nanosuspension was stable, safe, and capable of delivering drug to the brain via nasal route without any harm to other organs and in controlled manner and may be considered as a promising alternative route for oral drug delivery for management of refractory seizures